Cytek Biosciences (CTKB) Net Income towards Common Stockholders (2020 - 2026)
Cytek Biosciences (CTKB) posted Net Income towards Common Stockholders of -$18.9 million for Q1 2026, up 57.2% on a QoQ basis from -$44.1 million in Q4 2025, and down 65.46% year-over-year from -$54.6 million in Q1 2025.
Cytek Biosciences (CTKB) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Cytek Biosciences' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$18.9 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 65.46% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$74.0 million (down 557.69% YoY) and the FY2025 annual result came in at -$66.5 million, down 1005.3% from the prior year.
- Net Income towards Common Stockholders was -$18.9 million for Q1 2026 at Cytek Biosciences, up from -$44.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $9.6 million in Q4 2024 and bottomed at -$44.1 million in Q4 2025.
- A 5-year average of -$5.9 million and a median of -$5.5 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 381.5% in 2022, while the deepest fall reached 2081.37% in 2022.
- Cytek Biosciences' Net Income towards Common Stockholders stood at $3.5 million in 2022, then jumped by 55.94% to $5.5 million in 2023, then soared by 75.23% to $9.6 million in 2024, then plunged by 557.08% to -$44.1 million in 2025, then jumped by 57.2% to -$18.9 million in 2026.
- Business Quant data shows CTKB's Net Income towards Common Stockholders at -$18.9 million in Q1 2026, -$44.1 million in Q4 2025, and -$5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Cytek Biosciences | 565.66 Mn | 499.96 Mn | 21.25 Mn | -18.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -44.08 Mn |
| Sep 30, 2025 | -5.48 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Mar 31, 2025 | -11.40 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Sep 30, 2024 | 941,000.00 |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -6.17 Mn |
| Dec 31, 2023 | 5.50 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Jun 30, 2023 | -4.39 Mn |
| Mar 31, 2023 | -6.81 Mn |
| Dec 31, 2022 | 3.53 Mn |
| Sep 30, 2022 | 1.67 Mn |
| Jun 30, 2022 | -598,000.00 |
| Mar 31, 2022 | -2.02 Mn |
| Sep 30, 2021 | 346,000.00 |
| Mar 31, 2021 | 102,000.00 |
| Dec 31, 2020 | 575,000.00 |